European Pharma Stocks' Underperformance Shouldn't Last

Dow Jones

07/17

1413 GMT - European pharma stocks are lagging behind the broader market, but the sector should benefit as investors start to look for trades beyond big tech, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. This year's underperformance came after pricing deals with the Trump administration at the end of last year boosted the sector, Intron says. "We do not believe investors have fallen out of love with pharma, it is just that many believe the sector is up with events for now," the analysts say. Upcoming strategy updates from companies like GSK, Novo Nordisk and Roche, and potential gains from AI should help pharma stocks, they add. Intron says it favors UCB, AstraZeneca, Roche and Novartis in the near term. The Stoxx Europe 600 Health Care index rises 0.3%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 17, 2026 10:13 ET (14:13 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2652286740"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2652286740\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2652286740?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652286740","market":"fut","top_or_hot":-1,"title":"European Pharma Stocks' Underperformance Shouldn't Last","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1413 GMT - European pharma stocks are lagging behind the broader market, but the sector should benefit as investors start to look for trades beyond big tech, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. This year's underperformance came after pricing deals with the Trump administration at the end of last year boosted the sector, Intron says. \"We do not believe investors have fallen out of love with pharma, it is just that many believe the sector is up with events for now,\" the analysts say. Upcoming strategy updates from companies like GSK, <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> and Roche, and potential gains from AI should help pharma stocks, they add. Intron says it favors UCB, AstraZeneca, Roche and Novartis in the near term. The Stoxx Europe 600 Health Care index rises 0.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 10:13 ET (14:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>European Pharma Stocks' Underperformance Shouldn't Last</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEuropean Pharma Stocks' Underperformance Shouldn't Last\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-17 22:13</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1413 GMT - European pharma stocks are lagging behind the broader market, but the sector should benefit as investors start to look for trades beyond big tech, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. This year's underperformance came after pricing deals with the Trump administration at the end of last year boosted the sector, Intron says. \"We do not believe investors have fallen out of love with pharma, it is just that many believe the sector is up with events for now,\" the analysts say. Upcoming strategy updates from companies like GSK, <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> and Roche, and potential gains from AI should help pharma stocks, they add. Intron says it favors UCB, AstraZeneca, Roche and Novartis in the near term. The Stoxx Europe 600 Health Care index rises 0.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 10:13 ET (14:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPV","symbol_name":"ProShares UltraShort MSCI Europe","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2652286740","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652286740","pubTimestamp":1784297580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1413 GMT - European pharma stocks are lagging behind the broader market, but the sector should benefit as investors start to look for trades beyond big tech, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. This year's underperformance came after pricing deals with the Trump administration at the end of last year boosted the sector, Intron says. \"We do not believe investors have fallen out of love with pharma, it is just that many believe the sector is up with events for now,\" the analysts say. Upcoming strategy updates from companies like GSK, Novo Nordisk and Roche, and potential gains from AI should help pharma stocks, they add. Intron says it favors UCB, AstraZeneca, Roche and Novartis in the near term. The Stoxx Europe 600 Health Care index rises 0.3%.  Dow Jones NewswiresJuly 17, 2026 10:13 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"EPV":"ProShares UltraShort MSCI Europe","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","NVOX":"2倍做多NVO ETF-Defiance","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","PPH":"VanEck Pharmaceutical ETF","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","GSK":"葛兰素史克","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","AZN":"阿斯利康","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4578":"CAR-T","03165":"华夏欧优股对冲","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","GSKH":"GSK plc ADRhedged","CANC":"TEMA ONCOLOGY ETF","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","HRTS":"Tema Heart & Health ETF","BK4588":"碎股","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4568":"美国抗疫概念","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4007":"制药","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","OZEM":"Roundhill GLP-1 & Weight Loss ETF","NVS":"诺华","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4599":"减肥药","RHHBY":"罗氏控股","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF"},"translate_title":"欧洲制药股表现不佳不应持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOX":0.6,"PPH":0.6,"NVS":1.86,"AZN":1.86,"THNR":0.6,"CANC":0.6,"EPV":1.84,"MEDX":0.6,"03165":0.6,"GSK.UK":0.6,"HRTS":0.6,"GSK":1.87,"RHHBY":1.89,"NVO":1.87,"OZEM":0.6,"GSKH":0.6,"AZNH":0.6,"NVOH":0.6},"content_text":"1413 GMT - European pharma stocks are lagging behind the broader market, but the sector should benefit as investors start to look for trades beyond big tech, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. This year's underperformance came after pricing deals with the Trump administration at the end of last year boosted the sector, Intron says. \"We do not believe investors have fallen out of love with pharma, it is just that many believe the sector is up with events for now,\" the analysts say. Upcoming strategy updates from companies like GSK, Novo Nordisk and Roche, and potential gains from AI should help pharma stocks, they add. Intron says it favors UCB, AstraZeneca, Roche and Novartis in the near term. The Stoxx Europe 600 Health Care index rises 0.3%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2026 10:13 ET (14:13 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}